Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results

- Call will be held on Tuesday, July 25th beginning at 10 a.m. EDT -

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), announced today that it will hold a conference call with PAH experts on Tuesday, July 25th at 10 a.m. EDT. Gossamer’s management team will be joined by world-renowned PAH key opinion leaders, Dr. Ray Benza, Dr. Ardi Ghofrani, and Dr. Jim White to discuss the upcoming PROSERA Phase 3 study and an interim update of the Phase 2 TORREY open-label extension.

The live audio webcast may be accessed through the “Events / Presentations” page in the “Investors” section of the Company's website at www.gossamerbio.com. Alternatively, the conference call may be accessed through the following:

Date / Time: July 25, 10:00 a.m. EDT Domestic Dial-in Number: 1-800-285-6670 International Dial-in Number: 713-481-0091 Conference Reference: Seralutinib Program Update Call Live Webcast: https://edge.media-server.com/mmc/p/qzyj9utp

A replay of the audio webcast will be available for 30 days on the “Investors” section of the Company's website, www.gossamerbio.com.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients suffering from, pulmonary hypertension.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230724758177/en/

For Investors and Media: Bryan Giraudo, Chief Operating Officer and Chief Financial Officer Gossamer Bio Investor Relations ir@gossamerbio.com

Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Nov 2023 to Dec 2023